2023
Fatty acid binding proteins in multiple myeloma Diedrich C, Maksimos M, Azab AK. Trends Mol Med. 2023 Jun 13:S1471-4914(23)00101-6
E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma Maksimos M, Muz B, Magnani JL, and Azab AK. Blood Cancer J. 2023 Apr 7;13(1):48.
2022
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma Darawshi O, Muz B, Naamat SG, Praveen B, Mahameed M, Goldberg K, Dipta P, Shmuel M, Forno F, Boukeileh S, Pahima H, Hermann J, Raab MS, Poos AM, Weinhold N, Rosenbluh C, Gatt ME, Palm W, Azab AK, Tirosh B. Cell Death Dis. 2022 Nov 18;13(11):969
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S, Sattler M, Azab AK, Sun J, Muz B, Sanchez D, Toure A, Stone RM, Galinsky I, Winer E, Gleim S, Gkountela S, Kedves A, Harrington E, Abrams T, Zoller T, Vaupel A, Manley P, Faller M, Chung B, Chen X, Busenhart P, Stephan C, Calkins K, Bonenfant D, Thoma CR, Forrester W, Griffin JD. Blood Cancer J. 2022 Jul 19;12(7):110.
Synthesis, equilibrium, and biological study of a C-7 glucose boronic acid derivative as a potential candidate for boron neutron capture therapy B Muz, AK Azab, L Confalonieri, E Del Grosso, S Fallarini, D Imperio, Panza L. S. Bioorganic & Medicinal Chemistry. 2022. 116659.
Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma Waldschmidt JM, Fruttiger SJ, Wider D, Jung J, Thomsen AR, Hartmann TN, Duyster J, Hug MJ, Azab KA, Jung M, Wäsch R, Engelhardt M. J Cancer Res Clin Oncol. 2022. 148(5):1045-1055
Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy Alhallak K, Sun J, Muz B, Jeske A, O’Neal J, Ritchy JK, Achilefu S, DiPersio JF, Azab AK. J Cell Mol Med. 2022, 26(3):940-944.
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, Adebayo O, Bash H, Chen Y, Maksimos M, Muz B, Azab AK. 2022. 10(4):e003975
2021
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma Alhallak K, Jeske A, de la Puente P, Sun J, Fiala M, Azab F, Muz B, Sahin I, Vij R, DiPersio JF, Azab AK. Sci Rep. 2021, 11(1):19343.
Full article: 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance Alhallak K, de la Puente P, Jeske A, Sun J, Muz B, Rettig MP, Sahin I, Weisberg EL, Griffin JD, Reagan JL, DiPersio JF, Azab AK. Leuk Lymphoma. 2021. 62(10):2457-2465.
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia Alhallak K, Sun J, Muz B, Jeske A, Yavner J, Bash H, Park C, Lubben B, Adebayo O, Achilefu S, DiPersio JF, Azab AK. Oncotargets. 2021, 12(19):1878-1885.
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy Alhallak K, Sun J, Wasden K, Guenthner N, O’Neal J, Muz B, King J, Kohnen D, Vij R, Achilefu S, DiPersio JF, Azab AK. Leukemia. 2021 35(8):2346-2357.
Synthesis and Characterisation of a Boron-Rich Symmetric Triazine Bearing a Hypoxia-Targeting Nitroimidazole Moiety Bünning T, Panza L, Azab AK, Muz B, Fallarini S, Imperio D. Symmetry. 2021. 13, 202
CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies Sun J, Chen Y, Lubben B, Adebayo O, Muz B, Azab AK. Leuk Res Rep. 2021,16:100268
Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, Lubben B, Adebayo O, Khaskiah A, Azab AK. Cancers. 2021. 13 (12), 2853.
Targeting E-selectin to Tackle Cancer Using Uproleselan Muz B, Abdelghafer A, Markovic M, Yavner J, Melam A, Salama NN, Azab AK. Targeting E-selectin to Tackle Cancer Using Uproleselan. Cancers. 2021. 13(2), 335.
2020
Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile Federico C, Sun J, Muz B, Alhallak K, Cosper PF, Muhammad N, Jeske A, Hinger A, Markovina S, Grigsby P, Schwarz JK, Azab AK. Int J Radiat Oncol Biol Phys. 2020. 109 (5):1483-1494
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK. Nat Commun. 2020. 11(1): 6037
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K , Fiala M, King J, Kohnen D, Salama NN, Vij R, Azab AK. Cancers. 12(2). pii: E305.
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N. Cancers. 2020 Jan 30;12(2). pii: E320.
2019
A Short and Convenient Synthesis of closo‐Dodecaborate Sugar Conjugates Imperio D, Muz B, Azab AK, Fallarini S, Lombardi G, Panza L. European Journal of Organic Chemistry. 2019. (43).
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Am J Hematol. 2019. 94 (11):1244-1253.
Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy Luderer MJ, Muz B, Alhallak K, Sun J, Wasden K, Guenthner N, de la Puente P, Federico C, and Azab AK. Pharmaceutical Research. 2019. 7;36(10):144.
CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia Muz B, Bandara N, Mpoy C, Azab F, Alhallak K, Sun J, Rogers BE, and Azab AK. Cancer Biology and Therapy. 2019. 1:1-9.
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy Muz B, Azab F, Fiala M, King J, Kohnen D, Fogler WE, Smith T, Magnani JL, Vij R, and Azab AK. Blood Cancer Journal. 2019. 9(9):68.
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, and Azab AK. Haematologica. 2019. 104(7):e310-e313
2018
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK. J Control Release. 2018, 270:158-176.
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors de la Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B, Kapoor V, Goddu SM, Salama NN, Tsien C, Thotala D, Shoghi K, Rogers B, Azab AK. Journal of Pharmaceutical Sciences. 2018, 107(3):922-933
2017
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD. Oncotarget. 2017. 8(66):109973-109984
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker G, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M. British Journal of Haematology. 2017. 179(1):36-49.
Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy Imai T, Muz B, Yeh CH, Yao J, Zhang R, Azab AK, Wang L. Cancer Biol Ther. 2017. 18(2):101-105.
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma Muz B, Azab F, de la Puente P, Landesman Y, Azab AK. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Translational Oncology 2017. 04.01069.
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK. Leuk Lymphoma. 2017 58(12):2916-2925.
The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma Burwick N, Zhang MY, de la Puente P, Azab AK, Hyun TS, Ruiz-Gutierrez M, Sanchez-Bonilla M, Nakamura T, Delrow JJ, MacKay VL, Shimamura A. Leuk Res. 2017. 55:23-32.
Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma de la Puente P, Azab AK. European Journal of Hematology, 2017 98(6):529-541.
2016
A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B, Azab AK. Pharm Res. 2016. 33(10):2530-9
Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma de la Puente P, Quan N, Soo Hoo R, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, and Azab AK. Haematologica. 2016. 101(7):e307.
MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, and Azab AK. Blood Cancer Journal. 2016. 6:e399
A CD138‐independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma Muz B, de la Puente P, Azab F, Luderer M, King J, Vij R, Azab AK. British Journal of Hematology. 2016. 173(1):70-81.
Drug Delivery Approaches for the Treatment of Cervical Cancer Ordikhani F, Erdem Arslan M, Marcelo R, Sahin I, Grigsby P, Schwarz JK, Azab AK. Pharmaceutics. 2016. 8(3).
Biological Insights into Myeloma and Other B Cell Malignancies (hindawi.com) Fulciniti M, Amodio N, Cea M, Maiso P, and Azab AK. BioMed Research International. 2016: 521809
Spotlight on ixazomib: potential in the treatment of multiple myeloma Muz B, Ghazarian R, Ou M, Luderer M, Kusdono H, Salama NN, Azab AK. Journal Drug Design, Development and Therapy. 2016. 10:217-26
2015
Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK. Mol Cancer Res. 2015 13(2):263-72.
Stem Cell Transfusion Restores Immune Function in Radiation-Induced Lymphopenic C57BL/6 Mice Kapoor V, Khudanyan A, de la Puente P, Campian J, Hallahan DE, Azab AK*, Thotala D*. Cancer Res. Cancer Res. 2015. 75(17):3442-553. (*Co-Corresponding Authors)
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK. Biomaterials 2015, 73:70-84.
Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK. Leukemia Research. 2015. 39:1299-1308
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK. Leukemia and Lymphoma. 2015. 16:1-10.
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK. BioMed Research International. 2015, 2015:417586.
Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy Luderer MJ, de la Puente P, Azab AK. 2015. 32(9):2824-36.
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy Muz B, de la Puente P, Azab F, Azab AK. Hypoxia. 2015.
2014
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination Sahin I, Moschetta M, Mishima Y, Glavey SV, Tsang B, Azab F, Manier S, Zhang Y, Maiso P, Sacco A, Azab AK, Roccaro AM, Ghobrial IM. Blood Cancer Journal. 2014. 4:e204.
The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM. Laboratory Investigation. 2014. 94(8):881-92.
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma‐induced resistance Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R and Azab AK. British Journal of Hematology. 2014. 165(1):89-101
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan‐class I PI3K inhibitor, buparlisib Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, Roccaro AM, Azab AK*, Ghobrial IM*. Am J Hematol. 2014. 89(11):1030-6. (* Co-Corresponding Authors)
CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma Azab AK, Sahin I, Azab F, Moschetta M, Mishima Y, Burwick N, Zimmermann J, Romagnoli B, Patel K, Chevalier E, Roccaro AM, Ghobrial IM. Blood. 2014. 124(12):1905-14.
Hypoxia promotes stem cell-like phenotype in multiple myeloma cells Muz B, de la Puente P, Azab F, Luderer M, Azab AK. Blood Cancer J. 2014 (4):e262.
The role of P-glycoprotein in drug resistance in multiple myelomaAbraham J, Salama NN and Azab AK. Leukemia and Lymphoma. 2014. 5:1-8
MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma de la Puente P, Muz B, Azab F, Luderer M, Azab AK. 2014. 2014:976567.
Delivery systems for brachytherapy de la Puente P and Azab AK. Delivery systems for brachytherapy. Journal of Controlled Release. 2014. 192:19-28.
The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies Muz B, de la Puente P, Azab F, Luderer M, Azab AK. Mol Cancer Res. 2014. 12(10):1347-54
2013
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. J Clin Invest. 2013. 123(8):3635
Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. PLoS One. 2013 Jun 13;8(6).
The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression Azab AK, Weisberg E, Sahin E, Liu F, Awwad R, Azab F, Griffin JD, and Ghobrial IM. Leukemia. 2013. 27(4):961-4.
Azab F, Muz B, de la Puente P, Salama NN and Azab AK. Monograph: NPV-BKM-120.Drugs Fut. 2013. 38(2): 73
Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression de la Puente P, Muz B, Azab F, and Azab AK.2013. 119(13):3360-8.
Contemporary drug therapies for multiple myeloma de la Puente P and Azab AK. Drugs Today (Barc). 2013. 49(9):563-73
2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Blood. 2012. 120(25):5002-13.
Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Roccaro AM, Sacco A, Jia X, Banwit R, Maiso P, Azab F, Ludmila F, Manier S, Azab AK, and Ghobrial IM. Clin Cancer Res. 2012. 18(24):6609-22.
LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. Blood. 2012 Aug 23;120(8):1678-86.
Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia Azab F*, Azab AK*, Maiso P, Quang P, Roccaro AM, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Ghobrial IM. Clin Cancer Res. 2012 Jan 1;18(1):91-104 (*These authors have equal contribution)
Azab AK, Quang P, Azab F, Pitsillides C, Tompson B, Chonghaile T, Patton JT., Maiso P, Monrose V, Sacco A, Ngo HT, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM and Ghobrial IM. Blood. 2012. 119(6):1468-78.
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib Weisberg E*, Azab AK*, Kung AL, Bronson R, Ghobrial IM and Griffin JD. Leukemia. 2012. 26(5):985-90 (* These Authors have equal contribution)
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Blood. 2012. 119(24):5782-94.
2011
FGFR3 Is Overexpressed Waldenström Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation Azab AK, Azab F, Maiso P, Quang P, Roccaro AM, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Ghobrial IM. Clin Cancer Res. 2011. 17(13):4389-99.
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Zhang Y, Liu Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM. Clin Cancer Res. 2011. 11(1):109-11.
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion Neri P, Ren LW, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin CP, Duggan P; Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NsJ. Blood. 2011. 117(23):6202-13.
Defining the role of TORC1/2 in multiple myeloma Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro A, Rommel C, Ghobrial IM. Blood. 2011. 118(26):6860-70
2010
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Blood. 2010. 115(3):559-69.
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Clin Cancer Res. 2010. 16(3):1033-41.
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Blood. 2010. 115(20):4051-60.
Specific Detection of Gastric α-Antitrypsin by Immobilized Trypsin on PolyHEMA Films Khazanov E, Emanuel N, Azab AK, Yechezkel B, Yavin E, Rubinstein A. Mol Pharm. 2010 Jun 28. 7(4):944-52.
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JMJ, Azab AK, Moreau A-S, Rodig SCJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP. Journal of Biomedical Optics. 2010. 16(1):011006.
2009
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia Roccaro AM, SaccoA, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, and Ghobrial IM. Blood. 2009. 113(18):4391-402.
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma Roccaro AM, Sacco A, Leleu X, Thompson B, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, and Ghobrial IM. Blood. 2009. 113(26):6669-80.
In vitro and in vivo analysis of pulsatile biodegradation of mucoadhesive hydrogels Nadler-Milbauer M, Azab AK, Kleinstern J, Barenholz Y, Rubinstein A. J. Drug Del. Sci. Tech. 2009. 19 (4): 247-55.
Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia Ngo HT, Azab AK, Farag M, Jia X, Melhem MR, Runnels JM, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Clin. Cancer Res. 2009. 15(19):6035-41.
RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. Blood. 2009. 114(3):619-29.
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Azab AK, Runnels JM, Moreau AS, Azab F. Leleu XP, Jia X, Wright R, Beatriz O, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo T, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, and Ghobrial IM. Blood. 2009. 113(18):4341-51.
2008
Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Blood. 2008. 111(9):4752-63.
Targeting NF-κB in Waldenstrom macroglobulinemia Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC and Ghobrial IM. Blood. 2008. 111(10):5068-77.
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R and Ghobrial IM. Blood. 2008. 112(1):150-8.
The Metastatic Stage-dependent Mucosal Expression of Sialic Acid is a Potential Marker for Targeting Colon Cancer with Cationic Polymers Azab AK, Kleinstern J, Srebnik M, Rubinstein A. Pharm Res. 2008. 25(2):379-86.
2007
Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat Azab AK, Doviner V, Orkin B, Kleinstern J, Srebnik M, Nissan A, Rubinstein A. J Biomed Mater Res A. 2007. 83(2):414-22.
Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol Azab AK, Kleinstern J, Doviner V, Orkin B, Srebnik M, Nissan A, Rubinstein A. J Control Release. 2007. 123(2):116-22.
2005
Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers Azab AK, Srebnik M, Doviner V, Rubinstein A. J Control Release. 2005 106(1-2):14-25